Calcipotriol-captisol inclusion complex and corticosteroid in a novel fixed dose combination: evaluation on human epidermal keratinocyte cells

BADILLI F. U., BEŞİKCİ A., AMASYA G., Sen T., Tarimci N.

JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, vol.83, no.3-4, pp.363-368, 2015 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 83 Issue: 3-4
  • Publication Date: 2015
  • Doi Number: 10.1007/s10847-015-0572-1
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.363-368
  • Keywords: Calcipotriol, Captisol, Clobetasol propionate, Fixed dose combination, Human epidermal keratinocyte cell (HaCaT), PLGA microspheres, BETAMETHASONE DIPROPIONATE, VITAMIN-D, CLOBETASOL PROPIONATE, HALOBETASOL OINTMENT, PSORIASIS-VULGARIS, PROLIFERATION, EXPRESSION, HACAT, NANOPARTICLES, CYCLOSPORINE
  • Ankara University Affiliated: Yes


Psoriasis is a common chronic inflammatory dermatological disorder. Calcipotriol (CAL) and super potent corticosteroids are often used for the topical treatment of this disease. Because these active substances have serious and dose-dependent side effects, the application of combination therapies are preferred. By combination therapy, decreasing of the side effects of both active agents and increasing of the efficiency is provided. However, it is not possible to combine these two drugs in one formulation containing an aqueous phase since these substances show pH-dependent incompatibility. Therefore, for combination therapy, commercial products of corticosteroids and CAL are usually applied separately at different times of a day. The aim of this study was to prepare a fixed-dose combination of cyclodextrin complex of CAL and microspheres of clobetasol propionate in an aqueous semisolid vehicle for once daily application and to evaluate the in vitro antipsoriatic efficacy of this combination formulation on human epidermal keratinocyte cell line. The effect of fixed dose combination on the proinflammatory cytokine levels and keratinocyte proliferation were determined. It may be concluded that our new aqueous based fixed dose combination could be proposed as an alternative to the combination therapy which have been currently adopted in clinical practice.